Dorogun B N, Smirnov A A, Dobrovol'skiĭ A B, Pomerantsev E V, Staroverov I I
Kardiologiia. 1987 Mar;27(3):9-14.
Coronary thrombolysis by intracoronary and intravenous streptokinase (SK) is reported in myocardial infarction patients. Forty-two patients were examined within the first 6 hours of infarction: they were subjected to coronary-angiography on admission and 24 hours later, and their plasma fibrinogen levels were measured repeatedly for 2 days. SK administration was intracoronary in 24 patients and intravenous in 18. Rapid intravenous SK injection was not inferior to intracoronary administration in terms of efficiency. Although coronary reperfusion takes a somewhat longer time in cases of intravenous SK treatment, its technical simplicity and relative safety, as well as the fact that it can be started early suggest that it is a promising method of treatment for myocardial infarction.
据报道,在心肌梗死患者中采用冠状动脉内和静脉内注射链激酶(SK)进行冠状动脉溶栓治疗。42例患者在梗死的最初6小时内接受了检查:入院时和24小时后进行冠状动脉造影,并连续2天反复测量其血浆纤维蛋白原水平。24例患者采用冠状动脉内注射SK,18例采用静脉内注射。就疗效而言,快速静脉内注射SK并不逊色于冠状动脉内给药。尽管静脉内SK治疗时冠状动脉再灌注所需时间稍长,但其技术简单、相对安全,且可早期开始治疗,这表明它是一种有前景的心肌梗死治疗方法。